DOI: 10.25881/20728255_2026_21_4_124

Authors

Shevchenko Yu.L.1, Melkumyants A.M.2, Stoyko Yu.M.1, Chernyago T.Yu. 1, Yashkin M.N.1, Popova K.V.1

1 Pirogov National Medical and Surgical Center, Moscow

2 Chazov National Medical Research Center of Cardiology, Moscow

Abstract

This review presents current data on the molecular organization and physiological functions of the endothelial glycocalyx, including its involvement in mechanoreception, regulation of vascular wall permeability, maintenance of the anticoagulant barrier, and control of leukocyte adhesion. The mechanisms of glycocalyx damage in type 2 diabetes mellitus are examined in detail: direct metabolic effects of hyperglycemia, activation of matrix metalloproteinases (MMP-2, -9), heparanase and hyaluronidases, as well as oxidative stress and inflammation. It is demonstrated that low shear stress in the venous bed, exacerbated by venous stasis and valve insufficiency, creates an additional risk factor for glycocalyx degradation and thrombus formation. Clinical consequences are described – from edema and chronic inflammation to trophic ulcers and venous thromboembolic complications. Biomarkers of damage (soluble syndecan-1, hyaluronan) and the prospects for their use in early diagnosis and prognosis of chronic venous disease in patients with type 2 diabetes mellitus are discussed. Therapeutic strategies are considered: strict glycemic control, the use of sulodexide, statins, SGLT2 inhibitors, GLP-1 receptor agonists, compression therapy, as well as experimental approaches (heparanase inhibitors, recombinant syndecan-1, gene therapy).

Keywords: chronic venous insufficiency, endothelial glycocalyx, diabetes mellitus, type 2, syndecan-1, shear stress, varicose ulcer, matrix metalloproteinases, sulodexide.

References

1. Muzy J, et al. Prevalence of diabetes mellitus and its complications and characterization of healthcare gaps based on triangulation of studies. 2021.

2. Branisteanu DE, Feodor T, Boda D, et al. Impact of chronic venous disease on quality of life: Results of vein alarm study. Exp Ther Med. 2019; 17(2): 1091-1096. doi: 10.3892/etm.2018.7064.

3. Matic M, Matic A, Djuran V, et al. Frequency of peripheral arterial disease in patients with chronic venous insufficiency. Iran Red Crescent Med J. 2016; 18(1): e20781. doi: 10.5812/ircmj.20781.

4. Bertoluci MC, Forti AC, Pititto BA. Diretriz da Sociedade Brasileira de Diabetes: Conectando Pessoas. 2024. doi: 10.5412848.

5. Kolluri R, Chung J, Kim S, Desai S, Marston W. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022; 27(1): 63-72. doi: 10.1177/1358863X211055146.

6. Castro ACF, Pitta GBB, da Rocha TSS, et al. Systematic review and meta-analysis of the impact of diabetes mellitus on chronic venous insufficiency. J Vasc Bras. 2025; 24: e20250006. doi: 10.1590/1677-5449.20250006.

7. Meissner MH, Gibson K, Gloviczki P, et al. The symptoms-varices-pathophysiology classification of pelvic venous disorders: A report of the American Vein & Lymphatic Society International Working Group on Pelvic Venous Disorders. Phlebology. 2021; 36(5): 342-360. doi: 10.1177/ 02683555211052756.

8. Kikuchi R, da Silva RA, de Azevedo AO, et al. Brazilian guidelines on chronic venous disease of the Brazilian Society of Angiology and Vascular Surgery. J Vasc Bras. 2023; 22: e20230064. doi: 10.1590/1677-5449. 20230064.

9. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005; 15(3): 175-184. doi: 10.1016/j.annepidem.2004.05.015.

10. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F; VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012; 31(2): 105-115.

11. Ortega MA, Fraile-Martinez O, García-Montero C, et al. Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. J Clin Med. 2021; 10(15): 3239. doi: 10.3390/jcm10153239.

12. Bouzeghrane F, Zhang Y, Thabet S, Cui X, Yang XP. Deep vein thrombosis resolution is impaired in diet-induced type 2 diabetic mice. J Vasc Surg. 2008; 48(6): 1575-1584. doi: 10.1016/j.jvs.2008.07.071.

13. Vigilance JE, Reid HL. Venodynamic and hemorheological variables in patients with diabetes mellitus. Arch Med Res. 2005; 36(5): 490-495. doi: 10.1016/j.arcmed.2005.03.040.

14. Del Río-Solá ML, Faúndez-Castillo G, García-Madrid C, et al. The cardiovascular impact of chronic venous disease: A systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2025; 102310. doi: 10.1016/j.jvsv.2025.102310.

15. Jarošíková R, Štvrtina S, Jarošíková M, Kováčová E, Vachulová A. Chronic venous disease and its intersections with diabetes mellitus. Physiol Res. 2023; 72(3): 280-289. doi: 10.33549/physiolres.935049.

16. Auzky O, Poredoš P, Kastelec D, Lunder M. Association between symptoms of chronic venous disease in the lower extremities and cardiovascular risk factors in middle-aged women. Int Angiol. 2011; 30(4): 335-341.

17. Maksimenko AV. Endothelial glycocalyx – an important constituent part of the double protective layer of the vascular wall: a diagnostic indicator and therapeutic target. Kardiologicheskii vestnik. 2016; 11(3): 94-100. (In Russ.)

18. Henry SM, Bovin NV. Kode Technology – a universal cell surface glycan modification technology. J R Soc N Z. 2019; 49(2): 100-113. doi: 10.1080/03036758.2019.1596127.

19. Dogné S, Flamion B. Endothelial glycocalyx impairment in disease: focus on hyaluronan shedding. Am J Pathol. 2020; 190(4): 768-780. doi: 10.1016/j.ajpath.2019.11.016.

20. Melkumyants AM. O roli endotelial’nogo glikokaliksa v mekhanogennoi regulyatsii soprotivleniya arterial’nykh sosudov. Uspekhi fiziol. nauk. 2012; 43(4): 45-58. (In Russ.)

21. Shevchenko YL, Stoyko YM, Melkumyants AM, Gudymovich VG, Yashkin MN. Znachenie glikokaliksa v razvitii patologii serdechno-sosudistoi sistemy. Angiologiya i sosudistaya khirurgiya. Zhurnal imeni akademika A.V. Pokrovskogo. 2025; 31(1): 7-18. (In Russ.) doi: 10.33029/1027-6661-2025-31-1-7-18.

22. Gromova OA, Torshin IY, Chuchalin AG. O vliyanii glikokaliksa na biosintez NO: rol’ sulodeksida. Meditsinskii sovet. 2025; 19(5): 192-201. (In Russ.) doi: 10.21518/ekb2025-123.

23. Dull RO, Hahn RG. The glycocalyx as a permeability barrier: basic science and clinical evidence. Crit Care. 2022; 26(1): 273. doi: 10.1186/ s13054-022-04154-2.

24. Diaz JA, Gianesini S, Khalil RA. Glycocalyx disruption, endothelial dysfunction and vascular remodeling as underlying mechanisms and treatment targets of chronic venous disease. Int Angiol. 2024; 43(6): 563-578. doi: 10.23736/S0392-9590.24.05234-1.

25. Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. Mechanotransduction and flow across the endothelial glycocalyx. Proc Natl Acad Sci USA. 2003; 100(13): 7988-7995. doi: 10.1073/pnas.1332808100.

26. Mitra R. Glycocalyx Therapy to Restore Anti-Atherosclerotic Endothelial Cell Function [dissertation]. Boston: Northeastern University; 2024.

27. Ofosu FA, Modi GJ, Blajchman MA, Buchanan MR, Johnson EA. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood. 1984; 64(3): 742-747.

28. Lipowsky HH. The endothelial glycocalyx as a barrier to leukocyte adhesion and its mediation by extracellular proteases. Ann Biomed Eng. 2012; 40(4): 840-848. doi: 10.1007/s10439-011-0427-x.

29. Raffetto JD, Ligi D, Maniscalco R, Khalil RA, Mannello F. Why venous leg ulcers have difficulty healing: overview on pathophysiology, clinical consequences, and treatment. J Clin Med. 2020; 10(1): 29. doi: 10.3390/ jcm10010029.

30. Tarbell JM, Pahakis MY. Mechanotransduction and the glycocalyx. J Intern Med. 2006; 259(4): 339-350. doi: 10.1111/j.1365-2796.2006.01620.x.

31. Ramnath RD, Butler MJ, Butler LM, et al. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease. Kidney Int. 2020; 97(5): 951-965. doi: 10.1016/j.kint.2019.12.027.

32. Reine TM, Vuong TT, Jenssen TG, Kolset SO. Matrix metalloproteinase- 9 mediated shedding of syndecan- 4 in glomerular endothelial cells. Microcirculation. 2019; 26(4): e12534. doi: 10.1111/micc.12534.

33. Kaur G, Pociute K, Gromnicova R, et al. Effect of high glucose on glycosaminoglycans in cultured retinal endothelial cells and rat retina. Glycobiology. 2022; 32(8): 720-734. doi: 10.1093/glycob/cwac025.

34. Gomez Toledo A, Smeds E, Tarbell JM, Frösen J. Endothelial glycocalyx turnover in vascular health and disease: rethinking endothelial dysfunction. Annu Rev Biochem. 2025; 94. doi: 10.1146/annurev-biochem-062324-122654.

35. Bayam E, Gunesli ZB, Yanik A, et al. The emerging role of heparanase in cardiovascular diseases: Pathophysiology, clinical outcomes, and therapeutic perspectives. J Thromb Thrombolysis. 2026; 1-16. doi: 10.1007 /s11239-026-00000-0.

36. Hiebert LM. Heparan sulfate proteoglycans in diabetes. Semin Thromb Hemost. 2021; 47(3): 261-273. doi: 10.1055/s-0040-1722625.

37. Li Z, Yang Y, Wang Y, et al. Roles of endovascular calyx related enzymes in endothelial dysfunction and diabetic vascular complications. Front Pharmacol. 2020; 11: 590614. doi: 10.3389/fphar.2020.590614.

38. Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol. 2018; 38(7): 1427-1439. doi: 10.1161/ATVBAHA.118.310964.

39. Rajabloo Y, Jafari S, Zarei M, et al. Syndecans and diabetic complications: A narrative review. Am J Med Sci. 2024; 368(2): 99-111. doi: 10.1016/j.amjms.2024.02.011.

40. Ferreira-Divino LF, de Oliveira Faria AP, de Almeida-Pititto B, et al. Endothelial dysfunction markers syndecan-1 and thrombomodulin are associated with higher albuminuria levels in type 2 diabetes with no history of clinical cardiovascular disease. J Diabetes Complications. 2024; 38(11): 108879. doi: 10.1016/j.jdiacomp.2024.108879.

41. Kakutani Y, Shikuma J, Shintani A, et al. Association of serum syndecan-1 concentrations with albuminuria in type 2 diabetes. Diab Vasc Dis Res. 2024; 21(4): 14791641241278362. doi: 10.1177/14791641241278362.

42. Bol ME, van den Heuvel ER, Houterman S, et al. Multimodal measurement of glycocalyx degradation during coronary artery bypass grafting. Front Med (Lausanne). 2022; 9: 1045728. doi: 10.3389/fmed.2022. 1045728.

43. Kakutani Y, Shikuma J, Shintani A, Yatsu K, Shoji T. 433-P: Syndecan-1, a marker of endothelial glycocalyx degradation, is associated with albuminuria in type 2 diabetes. Diabetes. 2023; 72(S1): 433-P. doi: 10.2337/ db23-433-P.

44. Wang J, Zhang Q, Liu Y, Li Y, Wang H, Chen L, et al. Insulin increases shedding of syndecan-1 in the serum of patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009; 86(2): 83-88. doi: 10.1016/j.diabres. 2009.08.001.

45. Wang G, Tarbell JM, Zhang X, Liu Y, Luo JD. Shear stress regulation of endothelial glycocalyx structure is determined by glucobiosynthesis. Arterioscler Thromb Vasc Biol. 2020; 40(2): 350-364. doi: 10.1161/ ATVBAHA.119.313559.

46. Bai K, Wang W. Shear stress-induced redistribution of the glycocalyx on endothelial cells in vitro. Biomech Model Mechanobiol. 2014; 13(2): 303-311. doi: 10.1007/s10237-013-0500-3.

47. Foote CA, Soares RN, Ramirez-Perez FI, et al. Endothelial glycocalyx. Compr Physiol. 2022; 12(4): 3781-3811. doi: 10.1002/cphy.c210029.

48. Kalagara T, Moutsatsos P, Mendez E, Tarbell JM, Lopez JA. The Endothelial Glycocalyx Contributes to the Anchorage of von Willebrand Factor Fibers to the Vascular Endothelium. Hamostaseologie. 2019; 39(S 01): SY03-1-AB. doi: 10.1055/s-0039-1693068.

49. Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Lessard D, Spencer FA. Venous thromboembolism in patients with diabetes mellitus. Am J Med. 2012; 125(7): 709-716. doi: 10.1016/j.amjmed.2011.12.004.

50. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009; 28(4): 401-409. doi: 10.1007/s11239-009-0371-7.

51. AC FM. Medical significance of endothelial glycocalyx. Part 2: Its role in vascular diseases and in diabetic complications. Arch Cardiol Mex. 2014; 84(2): 110-116. doi: 10.1016/j.acmx.2013.10.008.

52. Shakya S, Wang Y, Liu Y, Li H. Hyperglycemia-induced changes in hyaluronan contribute to impaired skin wound healing in diabetes: review and perspective. Int J Cell Biol. 2015; 2015: 701738. doi: 10.1155/2015/701738.

53. Machin DR, Bloom SI, Richey RE, Lesniewski LA, Donato AJ. Therapeutic strategies targeting the endothelial glycocalyx. Curr Opin Clin Nutr Metab Care. 2023; 26(6): 543-550. doi: 10.1097/MCO.0000000000000976.

54. Wang G, Tarbell JM, Zhang X, Liu Y, Luo JD. Endothelial glycocalyx hyaluronan: regulation and role in prevention of diabetic complications. Am J Pathol. 2020; 190(4): 781-790. doi: 10.1016/j.ajpath.2019.11.018.

55. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53(12): 2646-2655. doi: 10.1007/ s00125-010-1910-x.

56. Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33(3): 243-254.

57. Katorkin SE. Znachenie endotelial’noi protektsii pri lechenii patsientov s khronicheskimi zabolevaniyami ven S6 klassa i sakharnym diabetom 2 tipa. Angiologiya i sosudistaya khirurgiya. 2015; 21(3): 99-106. (In Russ.)

58. Katorkin SE, Mel’nikov MA, Kravtsov PF. Effektivnost’ sulodeksida v lechenii patsientov s khronicheskimi zabolevaniyami ven nizhnikh konechnostei S1-S3 klinicheskikh klassov po CEAP. Ambulatornaya khirurgiya. 2019; 1-2: 38-44. (In Russ.) doi: 10.21518/1995-1477-2019-1-2-38-44.

59. Andreozzi GM, Bignamini AA, Davì G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015; 132(20): 1891-1897. doi: 10.1161/CIRCULATIONAHA.115.016930.

60. Gurumurthy G, Thachil J. Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis. Semin Thromb Hemost. 2025. doi: 10.1055/ s-0045-1800000.

61. Shevchenko YuL, Stoyko YuM, Chernyago TYu, Yashkin MN. Osobennosti funktsional’nogo sostoyaniya endoteliya i mikrotsirkulyatsii u patsientov s varikoznoi bolezn’yu nizhnikh konechnostei klassa S4 po SEAR posle endovenoznoi lazernoi obliteratsii i farmakoterapii sulodeksidom. Flebologiya. 2022; 16(3): 213-219. (In Russ.) doi: 10.17116/flebo202216031213.

62. Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J Atheroscler Thromb. 2014; 21(10): 997-1010. doi: 10.5551/jat.24672.

63. Cuccurullo C, Iezzi A, Fazia ML, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006; 26(12): 2716-2723. doi: 10.1161/01.ATV.0000249630.02059.74.

64. Uthman L, Baartscheer A, Bleijlevens B, et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018; 9: 1575. doi: 10.3389/fphys.2018.01575.

65. Dabravolski SA, Sadykhov NK, Kartuesov AG, et al. Mitochondria-mediated cardiovascular benefits of sodium-glucose co-transporter 2 inhibitors. Int J Mol Sci. 2022; 23(10): 5371. doi: 10.3390/ijms23105371.

66. Ikonomidis I, Pavlidis G, Thymis J, et al. Effects of glucagon- like peptide- 1 receptor agonists, sodium-glucose cotransporter- 2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12- month treatment. J Am Heart Assoc. 2020; 9(9): e015716. doi: 10.1161/ JAHA.119.015716.

For citation

Shevchenko Yu.L., Melkumyants A.M., Stoyko Yu.M., Chernyago T.Yu. , Yashkin M.N., Popova K.V. Endothelial glycocalyx in chronic venous disease in patients with type 2 diabetes mellitus: role in pathogenesis and therapeutic perspectives. Bulletin of Pirogov National Medical & Surgical Center. 2026;21(4):124-130. (In Russ.) https://doi.org/10.25881/20728255_2026_21_4_124